[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Duloxetine.]
[B01AD01, streptokinase, The risk or severity of orthostatic hypotension and syncope can be increased when Streptokinase is combined with Duloxetine.]
[J01GA01, streptomycin, Duloxetine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Duloxetine.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01CG01, sulbactam, Duloxetine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Duloxetine can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Duloxetine can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Duloxetine can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Duloxetine can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Sulindac.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Duloxetine.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Duloxetine.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Duloxetine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Duloxetine.]
[L01CB02, teniposide, The metabolism of Duloxetine can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, Duloxetine may increase the tachycardic activities of Terbutaline.]
[B01AE07, dabigatran etexilate, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Dabigatran etexilate.]
[G03BA03, testosterone, Duloxetine may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Duloxetine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Tetracaine is combined with Duloxetine.]
[S03AA02, tetracycline, Duloxetine may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Duloxetine.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[N04BC07, apomorphine, The risk or severity of orthostatic hypotension and syncope can be increased when Apomorphine is combined with Duloxetine.]
[L04AX02, thalidomide, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Duloxetine.]
[P02CA02, thiabendazole, Duloxetine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Duloxetine.]
[N05CA19, thiopental, The risk or severity of orthostatic hypotension and syncope can be increased when Thiopental is combined with Duloxetine.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Duloxetine.]
[N05AC02, thioridazine, The risk or severity of orthostatic hypotension and syncope can be increased when Thioridazine is combined with Duloxetine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Duloxetine.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Duloxetine.]
[G04BE06, moxisylyte, Duloxetine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Duloxetine.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Duloxetine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tiapride is combined with Duloxetine.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Duloxetine.]
[N02AX01, tilidine, The risk or severity of serotonin syndrome can be increased when Tilidine is combined with Duloxetine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Duloxetine.]
[P01AB02, tinidazole, Duloxetine may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Duloxetine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Tolazamide.]
[M02AX02, tolazoline, The risk or severity of orthostatic hypotension and syncope can be increased when Tolazoline is combined with Duloxetine.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Duloxetine.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Duloxetine.]
[C01DX11, trapidil, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Trapidil.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Duloxetine.]
[L01XF01, tretinoin, The risk or severity of orthostatic hypotension and syncope can be increased when Tretinoin is combined with Duloxetine.]
[C03DB02, triamterene, The risk or severity of orthostatic hypotension and syncope can be increased when Triamterene is combined with Duloxetine.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Duloxetine.]
[C03AA06, trichlormethiazide, The risk or severity of hyponatremia can be increased when Duloxetine is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Duloxetine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Duloxetine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluperidol is combined with Duloxetine.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Duloxetine.]
[N04AA01, trihexyphenidyl, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Duloxetine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Duloxetine.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Duloxetine.]
[R06AC04, tripelennamine, The metabolism of Duloxetine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Duloxetine.]
[A03BB01, butylscopolamine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Duloxetine.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Duloxetine.]
[C09CA09, azilsartan medoxomil, The risk or severity of orthostatic hypotension and syncope can be increased when Azilsartan medoxomil is combined with Duloxetine.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Duloxetine.]
[R03DX07, roflumilast, Duloxetine may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Duloxetine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Duloxetine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Duloxetine can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Linagliptin.]
[J05AG05, rilpivirine, The metabolism of Duloxetine can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Urokinase.]
[S01AA28, vancomycin, Duloxetine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Duloxetine.]
[B01AF01, rivaroxaban, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Rivaroxaban.]
[R03AC18, indacaterol, Duloxetine may increase the tachycardic activities of Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Ticagrelor.]
[C08DA01, verapamil, The risk or severity of orthostatic hypotension and syncope can be increased when Verapamil is combined with Duloxetine.]
[N06AX09, viloxazine, The metabolism of Duloxetine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Duloxetine can be decreased when combined with Vinblastine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[B01AA03, warfarin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Warfarin.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Duloxetine.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Duloxetine.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Duloxetine.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Duloxetine.]
[L01EC01, vemurafenib, The metabolism of Duloxetine can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[M05BA05, tiludronic acid, Duloxetine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Duloxetine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Duloxetine can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Duloxetine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Duloxetine is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Duloxetine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Duloxetine may increase the antiplatelet activities of Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Duloxetine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Duloxetine.]
[J01DH04, doripenem, Duloxetine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The risk or severity of orthostatic hypotension and syncope can be increased when Atenolol is combined with Duloxetine.]
[J02AC03, voriconazole, The metabolism of Duloxetine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Duloxetine.]
[S01FA01, atropine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Duloxetine may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Duloxetine.]
[B03XA04, peginesatide, Duloxetine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Duloxetine may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Duloxetine may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Duloxetine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Duloxetine.]
[G04BD12, mirabegron, The serum concentration of Duloxetine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Duloxetine can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, The serum concentration of Duloxetine can be decreased when it is combined with Enzalutamide.]
[B01AX01, defibrotide, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Defibrotide.]
[C01CA18, octopamine, Duloxetine may increase the tachycardic activities of Octopamine.]
[L01EX05, regorafenib, The metabolism of Duloxetine can be decreased when combined with Regorafenib.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Duloxetine.]
[D02BA02, octinoxate, Duloxetine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[N04BD02, rasagiline, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Duloxetine.]
[C08CA13, lercanidipine, The risk or severity of orthostatic hypotension and syncope can be increased when Lercanidipine is combined with Duloxetine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Mosapride is combined with Duloxetine.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Duloxetine.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Duloxetine.]
[V09IX04, fluorodeoxyglucose F18, Duloxetine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Duloxetine.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Duloxetine.]
[H01CB05, pasireotide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Duloxetine.]
[V08CA11, gadofosveset, Duloxetine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Duloxetine.]
[B01AF02, apixaban, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Apixaban.]
[A16AX08, teduglutide, Duloxetine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Duloxetine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Duloxetine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of orthostatic hypotension and syncope can be increased when Bendroflumethiazide is combined with Duloxetine.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Duloxetine.]
[G03XC05, ospemifene, The metabolism of Duloxetine can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Benperidol is combined with Duloxetine.]
[A10BK02, canagliflozin, The risk or severity of orthostatic hypotension and syncope can be increased when Canagliflozin is combined with Duloxetine.]
[M04AB03, benzbromarone, The metabolism of Duloxetine can be decreased when combined with Benzbromarone.]
[A06AX06, tegaserod, The metabolism of Tegaserod can be decreased when combined with Duloxetine.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Duloxetine.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin detemir.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Duloxetine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Pramlintide.]
[L03AA12, ancestim, Duloxetine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of bleeding can be increased when Celecoxib is combined with Duloxetine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Duloxetine.]
[L04AA18, everolimus, The metabolism of Duloxetine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The metabolism of Benzatropine can be decreased when combined with Duloxetine.]
[L01EC02, dabrafenib, The serum concentration of Duloxetine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Benzydamine.]
[L01EE01, trametinib, Duloxetine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Duloxetine.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Duloxetine.]
[V09AX05, florbetapir F-18, Duloxetine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Duloxetine.]
[C08EA02, bepridil, The risk or severity of orthostatic hypotension and syncope can be increased when Bepridil is combined with Duloxetine.]
[C02KX05, riociguat, The risk or severity of orthostatic hypotension and syncope can be increased when Riociguat is combined with Duloxetine.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Lixisenatide.]
[C02KX04, macitentan, Duloxetine may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Duloxetine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Duloxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Duloxetine.]
[J05AP08, sofosbuvir, Duloxetine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Duloxetine.]
[A10BK01, dapagliflozin, The risk or severity of orthostatic hypotension and syncope can be increased when Dapagliflozin is combined with Duloxetine.]
[C01CA27, droxidopa, Duloxetine may increase the tachycardic activities of Droxidopa.]
[C07AB04, acebutolol, The risk or severity of orthostatic hypotension and syncope can be increased when Acebutolol is combined with Duloxetine.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tasimelteon is combined with Duloxetine.]
[L04AA32, apremilast, The metabolism of Duloxetine can be increased when combined with Apremilast.]
[L02BG02, formestane, Duloxetine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S01ED02, betaxolol, The risk or severity of orthostatic hypotension and syncope can be increased when Betaxolol is combined with Duloxetine.]
[B01AE03, argatroban, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Argatroban.]
[V03AB34, fomepizole, Duloxetine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Duloxetine may increase the tachycardic activities of Bethanidine.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Duloxetine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Duloxetine can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Vorapaxar.]
[A03BA03, hyoscyamine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Alfaxalone is combined with Duloxetine.]
[A10BK03, empagliflozin, The risk or severity of orthostatic hypotension and syncope can be increased when Empagliflozin is combined with Duloxetine.]
[R03AC19, olodaterol, Duloxetine may increase the tachycardic activities of Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[D11AA01, glycopyrronium, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N05CM19, suvorexant, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Duloxetine can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Duloxetine can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Duloxetine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Dulaglutide.]
[A06AH03, naloxegol, The risk or severity of serotonin syndrome can be increased when Naloxegol is combined with Duloxetine.]
[N04AA02, biperiden, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Duloxetine.]
[S03AA06, gentamicin, Duloxetine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Duloxetine.]
[B01AA01, dicumarol, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Edoxaban.]
[N06AX11, mirtazapine, Duloxetine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Duloxetine can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Duloxetine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Duloxetine.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[A03AA09, difemerine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Duloxetine.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Eluxadoline is combined with Duloxetine.]
[B01AC25, cangrelor, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Cangrelor.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Duloxetine.]
[A04AD14, rolapitant, The metabolism of Duloxetine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Duloxetine.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Duloxetine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Duloxetine.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin degludec.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Duloxetine.]
[A02BC03, lansoprazole, The metabolism of Duloxetine can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Duloxetine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Duloxetine.]
[J02AC05, isavuconazole, The metabolism of Duloxetine can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Duloxetine.]
[L01XG03, ixazomib, Duloxetine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Acetohexamide.]
[M04AB05, lesinurad, Duloxetine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Duloxetine.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Duloxetine.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Duloxetine.]
[N04BC01, bromocriptine, The risk or severity of orthostatic hypotension and syncope can be increased when Bromocriptine is combined with Duloxetine.]
[A02AD05, aluminum magnesium silicate, Duloxetine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Duloxetine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Duloxetine.]
[C08CA01, amlodipine, The risk or severity of orthostatic hypotension and syncope can be increased when Amlodipine is combined with Duloxetine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Duloxetine.]
[C03CA02, bumetanide, The risk or severity of orthostatic hypotension and syncope can be increased when Bumetanide is combined with Duloxetine.]
[N01BB01, bupivacaine, The risk or severity of orthostatic hypotension and syncope can be increased when Bupivacaine is combined with Duloxetine.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Duloxetine.]
[N07BC01, buprenorphine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Duloxetine.]
[L01XX27, arsenic trioxide, The risk or severity of orthostatic hypotension and syncope can be increased when Arsenic trioxide is combined with Duloxetine.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Duloxetine.]
[M02AA03, clofezone, Duloxetine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Duloxetine.]
[S01GX07, azelastine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Duloxetine.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Balsalazide.]
[R03CC12, bambuterol, Duloxetine may increase the tachycardic activities of Bambuterol.]
[A06AH05, naldemedine, Duloxetine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Duloxetine.]
[N02BF02, pregabalin, The therapeutic efficacy of Duloxetine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Beclamide is combined with Duloxetine.]
[C09AA07, benazepril, The risk or severity of orthostatic hypotension and syncope can be increased when Benazepril is combined with Duloxetine.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Duloxetine.]
[P01CA02, benznidazole, Duloxetine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Duloxetine.]
[J05AF06, abacavir, Duloxetine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Tipranavir can be decreased when combined with Duloxetine.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Duloxetine.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Duloxetine.]
[L04AB02, infliximab, The metabolism of Duloxetine can be increased when combined with Infliximab.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Duloxetine.]
[N04BD03, safinamide, The risk or severity of serotonin syndrome can be increased when Safinamide is combined with Duloxetine.]
[J01MA23, delafloxacin, Duloxetine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Duloxetine.]
[L01BC06, capecitabine, The metabolism of Duloxetine can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Duloxetine.]
[C07AB07, bisoprolol, The risk or severity of orthostatic hypotension and syncope can be increased when Bisoprolol is combined with Duloxetine.]
[R03AC17, bitolterol, Duloxetine may increase the tachycardic activities of Bitolterol.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Duloxetine.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Duloxetine.]
[N04AA11, bornaprine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, The risk or severity of orthostatic hypotension and syncope can be increased when Nesiritide is combined with Duloxetine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromperidol is combined with Duloxetine.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Brotizolam is combined with Duloxetine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Duloxetine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Duloxetine.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Duloxetine.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Butriptyline is combined with Duloxetine.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Semaglutide.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Vinylbital is combined with Duloxetine.]
[R06AX18, acrivastine, Duloxetine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of orthostatic hypotension and syncope can be increased when Captopril is combined with Duloxetine.]
[L02BB05, apalutamide, Duloxetine may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Duloxetine may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A03AA03, camylofine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Duloxetine.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Duloxetine.]
[C07AG02, carvedilol, The risk or severity of orthostatic hypotension and syncope can be increased when Carvedilol is combined with Duloxetine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Duloxetine.]
[B02BX08, avatrombopag, The metabolism of Duloxetine can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, Duloxetine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Duloxetine.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01GB14, plazomicin, Duloxetine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Duloxetine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Duloxetine.]
[L01XX62, ivosidenib, The metabolism of Duloxetine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Duloxetine.]
[A16AX14, migalastat, Duloxetine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Duloxetine can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Duloxetine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Duloxetine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Carbromal is combined with Duloxetine.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Duloxetine.]
[D08AE05, chloroxylenol, Duloxetine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Lornoxicam.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Duloxetine.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Duloxetine.]
[L04AA39, emapalumab, The metabolism of Duloxetine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[L01EX13, gilteritinib, The therapeutic efficacy of Duloxetine can be decreased when used in combination with Gilteritinib.]
[A06AX05, prucalopride, Duloxetine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of orthostatic hypotension and syncope can be increased when Cilazapril is combined with Duloxetine.]
[B01AX07, caplacizumab, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Caplacizumab.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Duloxetine.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Duloxetine.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Duloxetine.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Duloxetine is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Duloxetine.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Duloxetine.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Brexanolone is combined with Duloxetine.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Duloxetine.]
[N05BA09, clobazam, The metabolism of Duloxetine can be decreased when combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Duloxetine.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Ubidecarenone.]
[C09CA06, candesartan, The metabolism of Duloxetine can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Duloxetine can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Duloxetine can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Duloxetine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Duloxetine.]
[L01EJ02, fedratinib, The metabolism of Duloxetine can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The metabolism of Pitolisant can be decreased when combined with Duloxetine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Duloxetine.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Duloxetine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin pork.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Duloxetine.]
[G03AC09, desogestrel, The metabolism of Duloxetine can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Duloxetine.]
[A16AX16, givosiran, The serum concentration of Duloxetine can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Duloxetine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Duloxetine.]
[S01XA12, dexpanthenol, Duloxetine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Duloxetine.]
[L01EX18, avapritinib, The metabolism of Duloxetine can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Lemborexant is combined with Duloxetine.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Duloxetine.]
[M01AX21, diacetylrhein, The metabolism of Duloxetine can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Duloxetine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Duloxetine.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Duloxetine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Duloxetine.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Duloxetine.]
[R02AA03, dichlorobenzyl alcohol, Duloxetine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Duloxetine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Duloxetine.]
[N02AA08, dihydrocodeine, The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Duloxetine.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Duloxetine.]
[M01AH02, rofecoxib, The metabolism of Duloxetine can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Duloxetine can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of orthostatic hypotension and syncope can be increased when Clevidipine is combined with Duloxetine.]
[C01BD07, dronedarone, The metabolism of Duloxetine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Duloxetine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Duloxetine.]
[A03AA08, dihexyverine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The risk or severity of orthostatic hypotension and syncope can be increased when Opicapone is combined with Duloxetine.]
[C01CA14, dopexamine, Duloxetine may increase the tachycardic activities of Dopexamine.]
[G04BD09, trospium, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Droxicam.]
[V08CA05, mangafodipir, Duloxetine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Duloxetine.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Duloxetine.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Duloxetine.]
[P01BB01, proguanil, The metabolism of Duloxetine can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Remimazolam is combined with Duloxetine.]
[L04AC19, satralizumab, The serum concentration of Duloxetine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Duloxetine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Duloxetine.]
[L01EX23, pralsetinib, The metabolism of Duloxetine can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of orthostatic hypotension and syncope can be increased when Chlorothiazide is combined with Duloxetine.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Duloxetine.]
[N05AA01, chlorpromazine, The risk or severity of orthostatic hypotension and syncope can be increased when Chlorpromazine is combined with Duloxetine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Duloxetine.]
[C03BA04, chlorthalidone, The risk or severity of orthostatic hypotension and syncope can be increased when Chlorthalidone is combined with Duloxetine.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Duloxetine.]
[A11CC05, cholecalciferol, The metabolism of Duloxetine can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Etifoxine is combined with Duloxetine.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Ethenzamide.]
[N02BA03, choline salicylate, Duloxetine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Vinpocetine is combined with Duloxetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Duloxetine.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Duloxetine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Duloxetine.]
[M01AX25, chondroitin sulfates, Duloxetine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[C01DX22, vericiguat, The risk or severity of orthostatic hypotension and syncope can be increased when Vericiguat is combined with Duloxetine.]
[L01EX21, tepotinib, The metabolism of Duloxetine can be decreased when combined with Tepotinib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Febarbamate is combined with Duloxetine.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Duloxetine.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Fenbufen.]
[C01CA19, fenoldopam, The risk or severity of orthostatic hypotension and syncope can be increased when Fenoldopam is combined with Duloxetine.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Duloxetine is combined with Fenozolone.]
[J01DD15, cefdinir, Duloxetine may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Duloxetine may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[N02BG07, flupirtine, Duloxetine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Duloxetine.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin human.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Duloxetine.]
[L03AB10, peginterferon alfa-2b, The metabolism of Duloxetine can be decreased when combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Duloxetine.]
[A02BA01, cimetidine, The metabolism of Duloxetine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Duloxetine.]
[V08CA04, gadoteridol, Duloxetine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Duloxetine.]
[S03AA07, ciprofloxacin, The metabolism of Duloxetine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Duloxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The metabolism of Citalopram can be decreased when combined with Duloxetine.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Duloxetine.]
[V09AB03, ioflupane I-123, Duloxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[V09AA01, technetium Tc 99m exametazime, Duloxetine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Duloxetine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Duloxetine.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Mefenamic acid.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Gliquidone.]
[R03CC13, clenbuterol, Duloxetine may increase the tachycardic activities of Clenbuterol.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Duloxetine.]
[L01EA06, asciminib, The metabolism of Duloxetine can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Duloxetine.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Duloxetine.]
[B01AD11, tenecteplase, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Tenecteplase.]
[N01BB10, levobupivacaine, The risk or severity of orthostatic hypotension and syncope can be increased when Levobupivacaine is combined with Duloxetine.]
[N06AA04, clomipramine, The risk or severity of orthostatic hypotension and syncope can be increased when Clomipramine is combined with Duloxetine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Duloxetine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Duloxetine.]
[C01EB24, mavacamten, The serum concentration of Duloxetine can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Tirzepatide.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Clothiapine is combined with Duloxetine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Duloxetine.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Duloxetine.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Duloxetine.]
[N05AH02, clozapine, The risk or severity of orthostatic hypotension and syncope can be increased when Clozapine is combined with Duloxetine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sotagliflozin.]
[J01GB12, arbekacin, Duloxetine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Duloxetine.]
[S02DA02, cocaine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Duloxetine.]
[L04AC21, bimekizumab, The metabolism of Duloxetine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of serotonin syndrome can be increased when Codeine is combined with Duloxetine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Duloxetine.]
[M04AC01, colchicine, Duloxetine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Duloxetine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[L04AA13, leflunomide, The metabolism of Duloxetine can be decreased when combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of orthostatic hypotension and syncope can be increased when Desflurane is combined with Duloxetine.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tropisetron is combined with Duloxetine.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ifenprodil is combined with Duloxetine.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Duloxetine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin glargine.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Duloxetine.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Duloxetine.]
[J05AB14, valganciclovir, Duloxetine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Duloxetine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Duloxetine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Duloxetine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Duloxetine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Duloxetine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Valdecoxib.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Duloxetine.]
[A03AX10, isometheptene, Duloxetine may increase the tachycardic activities of Isometheptene.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Duloxetine.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Parecoxib.]
[B01AB12, bemiparin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Duloxetine.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Duloxetine can be increased when it is combined with Imatinib.]
[C08CA09, lacidipine, The risk or severity of orthostatic hypotension and syncope can be increased when Lacidipine is combined with Duloxetine.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Duloxetine.]
[S01GX02, levocabastine, The risk or severity of adverse effects can be increased when Levocabastine is combined with Duloxetine.]
[N07BC04, lofexidine, The therapeutic efficacy of Duloxetine can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lormetazepam is combined with Duloxetine.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of orthostatic hypotension and syncope can be increased when Lisinopril is combined with Duloxetine.]
[A06AD01, magnesium carbonate, Duloxetine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Duloxetine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Medifoxamine is combined with Duloxetine.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Duloxetine is combined with Mefenorex.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Duloxetine.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Duloxetine.]
[J01DH02, meropenem, Duloxetine may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Duloxetine is combined with Adenosine.]
[N04AA03, methixene, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, Duloxetine may increase the tachycardic activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Duloxetine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Cyclobarbital is combined with Duloxetine.]
[C03DA04, eplerenone, The risk or severity of orthostatic hypotension and syncope can be increased when Eplerenone is combined with Duloxetine.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Melperone is combined with Duloxetine.]
[C03AA07, cyclopenthiazide, The risk or severity of hyponatremia can be increased when Duloxetine is combined with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Miglitol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Duloxetine.]
[N06AX07, minaprine, The risk or severity of serotonin syndrome can be increased when Minaprine is combined with Duloxetine.]
[S01XA18, cyclosporine, The metabolism of Duloxetine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of serotonin syndrome can be increased when Moclobemide is combined with Duloxetine.]
[N06BA07, modafinil, The metabolism of Duloxetine can be decreased when combined with Armodafinil.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Duloxetine can be decreased when used in combination with Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of orthostatic hypotension and syncope can be increased when Moexipril is combined with Duloxetine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Duloxetine.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of orthostatic hypotension and syncope can be increased when Conivaptan is combined with Duloxetine.]
[C02AC05, moxonidine, The risk or severity of orthostatic hypotension and syncope can be increased when Moxonidine is combined with Duloxetine.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Etoricoxib.]
[L01AX04, dacarbazine, Duloxetine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Duloxetine.]
[J04BA02, dapsone, The metabolism of Duloxetine can be decreased when combined with Dapsone.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Deanol is combined with Duloxetine.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Duloxetine.]
[A04AD11, nabilone, The risk or severity of orthostatic hypotension and syncope can be increased when Nabilone is combined with Duloxetine.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Nabumetone.]
[N07BB05, nalmefene, Duloxetine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Nordazepam is combined with Duloxetine.]
[C07AB12, nebivolol, The risk or severity of orthostatic hypotension and syncope can be increased when Nebivolol is combined with Duloxetine.]
[S01GX04, nedocromil, Duloxetine may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Nefazodone can be decreased when combined with Duloxetine.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Niaprazine is combined with Duloxetine.]
[C01DX16, nicorandil, Duloxetine may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, The metabolism of Duloxetine can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Duloxetine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Duloxetine.]
[C01CA05, norfenefrine, Duloxetine may increase the tachycardic activities of Norfenefrine.]
[R05DA06, normethadone, The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Duloxetine.]
[B01AX05, fondaparinux, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Duloxetine.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Olsalazine.]
[N06AA01, desipramine, The metabolism of Desipramine can be decreased when combined with Duloxetine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Duloxetine is combined with Desmopressin.]
[V04CH02, indigo carmine, Duloxetine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of orthostatic hypotension and syncope can be increased when Aliskiren is combined with Duloxetine.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Duloxetine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Oxiracetam is combined with Duloxetine.]
[N04AA08, dexetimide, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Duloxetine.]
[A03AA01, oxyphencyclimine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Duloxetine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Duloxetine.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Duloxetine.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Duloxetine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Duloxetine.]
[N02AC01, dextromoramide, The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Duloxetine.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Duloxetine.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Duloxetine.]
[B01AC04, clopidogrel, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Duloxetine.]
[P03AC04, permethrin, Duloxetine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Duloxetine.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Duloxetine.]
[V03AH01, diazoxide, The risk or severity of orthostatic hypotension and syncope can be increased when Diazoxide is combined with Duloxetine.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Duloxetine.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Dibenzepin is combined with Duloxetine.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Duloxetine.]
[R05DA08, pholcodine, Duloxetine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, The risk or severity of orthostatic hypotension and syncope can be increased when Diclofenamide is combined with Duloxetine.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Diclofenac.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[A03AA07, dicyclomine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Duloxetine may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of orthostatic hypotension and syncope can be increased when Pipamperone is combined with Duloxetine.]
[A03AB14, pipenzolate, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Duloxetine.]
[R03CC07, pirbuterol, Duloxetine may increase the tachycardic activities of Pirbuterol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Duloxetine.]
[L02AA01, diethylstilbestrol, The metabolism of Duloxetine can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The risk or severity of orthostatic hypotension and syncope can be increased when Isradipine is combined with Duloxetine.]
[D07XC04, diflucortolone, Duloxetine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Diflunisal.]
[C01AA05, digoxin, Duloxetine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Duloxetine.]
[N02AA03, hydromorphone, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Duloxetine.]
[L04AX04, lenalidomide, Duloxetine may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Duloxetine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Duloxetine can be decreased when combined with Treprostinil.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Duloxetine.]
[V03AB04, pralidoxime, Duloxetine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Pramocaine is combined with Duloxetine.]
[C08DB01, diltiazem, The risk or severity of orthostatic hypotension and syncope can be increased when Diltiazem is combined with Duloxetine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Duloxetine.]
[V03AB09, dimercaprol, Duloxetine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pridinol is combined with Duloxetine.]
[R06AB03, dimethindene, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, Duloxetine may increase the tachycardic activities of Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Duloxetine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Duloxetine.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Duloxetine can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Duloxetine.]
[A07DA01, diphenoxylate, The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Duloxetine.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Duloxetine.]
[C09AA06, quinapril, The risk or severity of orthostatic hypotension and syncope can be increased when Quinapril is combined with Duloxetine.]
[B01AC07, dipyridamole, The risk or severity of orthostatic hypotension and syncope can be increased when Dipyridamole is combined with Duloxetine.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Duloxetine.]
[B01AD10, drotrecogin alfa, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Quinupramine is combined with Duloxetine.]
[A03FA02, cisapride, The metabolism of Duloxetine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of orthostatic hypotension and syncope can be increased when Ramipril is combined with Duloxetine.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Duloxetine.]
[R03CC14, reproterol, Duloxetine may increase the tachycardic activities of Reproterol.]
[S01AX06, resorcinol, Duloxetine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Duloxetine can be decreased when combined with Rifamycin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Duloxetine.]
[N05AX08, risperidone, The metabolism of Risperidone can be decreased when combined with Duloxetine.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Levocetirizine is combined with Duloxetine.]
[N01BB09, ropivacaine, The risk or severity of orthostatic hypotension and syncope can be increased when Ropivacaine is combined with Duloxetine.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sunitinib.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Duloxetine.]
[G04BE08, tadalafil, Duloxetine may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Ketorolac.]
[C01EB18, ranolazine, The serum concentration of Duloxetine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Salsalate.]
[R03AC12, salmeterol, Duloxetine may increase the tachycardic activities of Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Duloxetine.]
[C01CA07, dobutamine, Duloxetine may increase the tachycardic activities of Dobutamine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Duloxetine.]
[C01CA04, dopamine, Duloxetine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Duloxetine.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Duloxetine.]
[L01DB01, doxorubicin, The metabolism of Duloxetine can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Duloxetine.]
[N01AB08, sevoflurane, The risk or severity of orthostatic hypotension and syncope can be increased when Sevoflurane is combined with Duloxetine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Duloxetine is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Duloxetine.]
[A12CA02, sodium sulfate, Duloxetine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Duloxetine may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Sultopride is combined with Duloxetine.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Duloxetine.]
[V04CX07, edrophonium, Duloxetine may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Duloxetine.]
[L01AX03, temozolomide, Duloxetine may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Tenoxicam.]
[G04CA03, terazosin, The risk or severity of orthostatic hypotension and syncope can be increased when Terazosin is combined with Duloxetine.]
[D01BA02, terbinafine, The metabolism of Duloxetine can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Duloxetine.]
[S01GA02, tetrahydrozoline, Duloxetine may increase the tachycardic activities of Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Tetrazepam is combined with Duloxetine.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Duloxetine.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiopropazate is combined with Duloxetine.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Duloxetine.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Duloxetine.]
[C09AA02, enalapril, The risk or severity of orthostatic hypotension and syncope can be increased when Enalapril is combined with Duloxetine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Duloxetine.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of serotonin syndrome can be increased when Toloxatone is combined with Duloxetine.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Duloxetine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Duloxetine.]
[C03CA04, torsemide, The risk or severity of orthostatic hypotension and syncope can be increased when Torasemide is combined with Duloxetine.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Duloxetine is combined with Tramazoline.]
[C09AA10, trandolapril, The risk or severity of orthostatic hypotension and syncope can be increased when Trandolapril is combined with Duloxetine.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Loprazolam is combined with Duloxetine.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Duloxetine.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Duloxetine.]
[A03AB08, tridihexethyl, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Triflusal.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Duloxetine.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Duloxetine.]
[N04AA12, tropatepine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Troxerutin.]
[R03CC11, tulobuterol, Duloxetine may increase the tachycardic activities of Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Duloxetine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Urapidil is combined with Duloxetine.]
[J01MA04, enoxacin, The metabolism of Duloxetine can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Veralipride is combined with Duloxetine.]
[L01CA04, vinorelbine, The metabolism of Duloxetine can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, Duloxetine may increase the tachycardic activities of Ephedrine.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Duloxetine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Venlafaxine.]
[C01CX07, xamoterol, Duloxetine may increase the tachycardic activities of Xamoterol.]
[S01GA03, xylometazoline, Duloxetine may increase the tachycardic activities of Xylometazoline.]
[C08CA12, mepirodipine, The risk or severity of orthostatic hypotension and syncope can be increased when Barnidipine is combined with Duloxetine.]
[S01EA01, epinephrine, Duloxetine may increase the tachycardic activities of Epinephrine.]
[N05CF02, zolpidem, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Duloxetine.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin glulisine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Zopiclone is combined with Duloxetine.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zotepine is combined with Duloxetine.]
[B01AD03, anistreplase, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Anistreplase.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of orthostatic hypotension and syncope can be increased when Guanfacine is combined with Duloxetine.]
[B01AC11, iloprost, The risk or severity of orthostatic hypotension and syncope can be increased when Iloprost is combined with Duloxetine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Duloxetine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Duloxetine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Duloxetine.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Duloxetine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Duloxetine.]
[L03AX05, pidotimod, Duloxetine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Duloxetine.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Duloxetine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, Duloxetine may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Duloxetine.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Duloxetine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Duloxetine.]
[V03AF05, amifostine, The risk or severity of orthostatic hypotension and syncope can be increased when Amifostine is combined with Duloxetine.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04AA05, profenamine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Duloxetine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Duloxetine.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Duloxetine.]
[C01CA01, etilefrine, Duloxetine may increase the tachycardic activities of Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Duloxetine.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Duloxetine.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Duloxetine.]
[R06AX12, terfenadine, The metabolism of Duloxetine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Duloxetine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Duloxetine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Duloxetine can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Duloxetine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Duloxetine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Dextran.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[A16AA01, levocarnitine, Duloxetine may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of orthostatic hypotension and syncope can be increased when Felodipine is combined with Duloxetine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Fenoprofen.]
[R03CC04, fenoterol, Duloxetine may increase the tachycardic activities of Fenoterol.]
[N02AB03, fentanyl, The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Duloxetine.]
[R03CC02, albuterol, Duloxetine may increase the tachycardic activities of Salbutamol.]
[B01AD05, plasmin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of orthostatic hypotension and syncope can be increased when Clofarabine is combined with Duloxetine.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Duloxetine.]
[G04BD02, flavoxate, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Duloxetine.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Duloxetine can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Duloxetine may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Duloxetine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Duloxetine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Duloxetine.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Melitracen is combined with Duloxetine.]
[V03AZ01, ethanol, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Duloxetine can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Duloxetine can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Duloxetine.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Duloxetine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Duloxetine.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Duloxetine.]
[L02BB01, flutamide, Duloxetine may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[S02AA17, fosfomycin, Duloxetine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[L01BC03, tegafur, Duloxetine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, Duloxetine may increase the tachycardic activities of Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Duloxetine.]
[G01AX06, furazolidone, The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Duloxetine.]
[J05AE10, darunavir, The metabolism of Duloxetine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of orthostatic hypotension and syncope can be increased when Furosemide is combined with Duloxetine.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Duloxetine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Duloxetine.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Duloxetine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Duloxetine.]
[S01AD09, ganciclovir, Duloxetine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Barbexaclone is combined with Duloxetine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bifemelane is combined with Duloxetine.]
[C10AB04, gemfibrozil, The metabolism of Duloxetine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Duloxetine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Duloxetine.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Duloxetine can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Duloxetine.]
[N01AH02, alfentanil, The risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Duloxetine.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of orthostatic hypotension and syncope can be increased when Dexmedetomidine is combined with Duloxetine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Duloxetine.]
[C05AE01, nitroglycerin, The risk or severity of orthostatic hypotension and syncope can be increased when Nitroglycerin is combined with Duloxetine.]
[C02CA04, doxazosin, The risk or severity of orthostatic hypotension and syncope can be increased when Doxazosin is combined with Duloxetine.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Duloxetine.]
[L01EX02, sorafenib, The metabolism of Duloxetine can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of orthostatic hypotension and syncope can be increased when Esmolol is combined with Duloxetine.]
[M01CB04, aurothioglucose, Duloxetine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Duloxetine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Fluindione.]
[C09AA09, fosinopril, The risk or severity of orthostatic hypotension and syncope can be increased when Fosinopril is combined with Duloxetine.]
[S01EX01, guanethidine, Duloxetine may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Duloxetine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Duloxetine.]
[N01AB01, halothane, The risk or severity of orthostatic hypotension and syncope can be increased when Halothane is combined with Duloxetine.]
[N05AH04, quetiapine, The risk or severity of orthostatic hypotension and syncope can be increased when Quetiapine is combined with Duloxetine.]
[N06BX13, idebenone, Duloxetine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin aspart.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Iprazochrome is combined with Duloxetine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Allobarbital is combined with Duloxetine.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of orthostatic hypotension and syncope can be increased when Losartan is combined with Duloxetine.]
[S01XA14, heparin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Heparin.]
[G03DC01, allylestrenol, Duloxetine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Mesalazine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Duloxetine.]
[R03CC05, hexoprenaline, Duloxetine may increase the tachycardic activities of Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Duloxetine.]
[C08CA10, nilvadipine, The risk or severity of orthostatic hypotension and syncope can be increased when Nilvadipine is combined with Duloxetine.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Nimesulide.]
[C09AA04, perindopril, The risk or severity of orthostatic hypotension and syncope can be increased when Perindopril is combined with Duloxetine.]
[C02DB02, hydralazine, The risk or severity of orthostatic hypotension and syncope can be increased when Hydralazine is combined with Duloxetine.]
[C03AA03, hydrochlorothiazide, The risk or severity of orthostatic hypotension and syncope can be increased when Hydrochlorothiazide is combined with Duloxetine.]
[R05DA03, hydrocodone, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The risk or severity of orthostatic hypotension and syncope can be increased when Hydroflumethiazide is combined with Duloxetine.]
[B05XA17, potassium acetate, Duloxetine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[G04BD06, propiverine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Duloxetine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Prothipendyl is combined with Duloxetine.]
[B05AA07, hetastarch, Duloxetine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[C02AC06, rilmenidine, Duloxetine may increase the tachycardic activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Ibuprofen.]
[B05XA08, sodium acetate, Duloxetine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Duloxetine.]
[L01AA06, ifosfamide, Duloxetine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of orthostatic hypotension and syncope can be increased when Sufentanil is combined with Duloxetine.]
[N06AA02, imipramine, The risk or severity of orthostatic hypotension and syncope can be increased when Imipramine is combined with Duloxetine.]
[L01CD01, paclitaxel, The risk or severity of orthostatic hypotension and syncope can be increased when Paclitaxel is combined with Duloxetine.]
[R01AD07, tixocortol, Duloxetine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of orthostatic hypotension and syncope can be increased when Tizanidine is combined with Duloxetine.]
[L01CE01, topotecan, Duloxetine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of orthostatic hypotension and syncope can be increased when Indapamide is combined with Duloxetine.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Indomethacin.]
[C02CA02, indoramin, The risk or severity of orthostatic hypotension and syncope can be increased when Indoramin is combined with Duloxetine.]
[A11HA07, inositol, Duloxetine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Duloxetine is combined with Milnacipran.]
[A03AA30, piperidolate, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Duloxetine may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Articaine is combined with Duloxetine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sitagliptin.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Duloxetine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Duloxetine.]
[R06AE01, buclizine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Duloxetine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Anagrelide.]
[C07AA01, alprenolol, The metabolism of Alprenolol can be decreased when combined with Duloxetine.]
[C03BA02, quinethazone, The risk or severity of hyponatremia can be increased when Duloxetine is combined with Quinethazone.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Duloxetine.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Iprindole is combined with Duloxetine.]
[N06AF05, iproniazid, The risk or severity of serotonin syndrome can be increased when Iproniazid is combined with Duloxetine.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Duloxetine.]
[N06AF01, isocarboxazid, The risk or severity of serotonin syndrome can be increased when Isocarboxazid is combined with Duloxetine.]
[P01AX06, atovaquone, The metabolism of Duloxetine can be decreased when combined with Atovaquone.]
[R03CC06, isoetharine, Duloxetine may increase the tachycardic activities of Isoetharine.]
[C09AA16, imidapril, The risk or severity of orthostatic hypotension and syncope can be increased when Imidapril is combined with Duloxetine.]
[N01AB06, isoflurane, The risk or severity of orthostatic hypotension and syncope can be increased when Isoflurane is combined with Duloxetine.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Duloxetine.]
[J04AC01, isoniazid, The metabolism of Duloxetine can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Duloxetine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Duloxetine may increase the tachycardic activities of Isoprenaline.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Exenatide.]
[C01DA14, isosorbide mononitrate, The risk or severity of orthostatic hypotension and syncope can be increased when Isosorbide mononitrate is combined with Duloxetine.]
[C05AE02, isosorbide dinitrate, The risk or severity of orthostatic hypotension and syncope can be increased when Isosorbide dinitrate is combined with Duloxetine.]
[D10BA01, isotretinoin, Duloxetine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of orthostatic hypotension and syncope can be increased when Isoxsuprine is combined with Duloxetine.]
[B01AE06, bivalirudin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Bivalirudin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Duloxetine.]
[S01AA24, kanamycin, Duloxetine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Duloxetine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Duloxetine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ketanserin is combined with Duloxetine.]
[B01AC22, prasugrel, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Duloxetine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of orthostatic hypotension and syncope can be increased when Olanzapine is combined with Duloxetine.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Ketoprofen.]
[L04AA24, abatacept, The metabolism of Duloxetine can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Duloxetine may increase the tachycardic activities of Arbutamine.]
[N04BC09, rotigotine, The risk or severity of orthostatic hypotension and syncope can be increased when Rotigotine is combined with Duloxetine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Duloxetine.]
[D10AX03, azelaic acid, Duloxetine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The risk or severity of orthostatic hypotension and syncope can be increased when Labetalol is combined with Duloxetine.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Amantadine.]
[A06AX03, lubiprostone, Duloxetine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Duloxetine.]
[C03CC01, ethacrynic acid, The risk or severity of orthostatic hypotension and syncope can be increased when Etacrynic acid is combined with Duloxetine.]
[N04BA01, levodopa, The risk or severity of orthostatic hypotension and syncope can be increased when Levodopa is combined with Duloxetine.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Duloxetine.]
[S01AA21, amikacin, Duloxetine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Duloxetine can be decreased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of orthostatic hypotension and syncope can be increased when Amiloride is combined with Duloxetine.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Duloxetine.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Lofepramine is combined with Duloxetine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Duloxetine.]
[C10AA02, lovastatin, The metabolism of Duloxetine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Duloxetine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Duloxetine.]
[L01EG01, temsirolimus, The metabolism of Duloxetine can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Duloxetine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Duloxetine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Duloxetine can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Duloxetine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, The risk or severity of orthostatic hypotension and syncope can be increased when Mannitol is combined with Duloxetine.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be decreased when combined with Duloxetine.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Duloxetine.]
[C02BB01, mecamylamine, The risk or severity of orthostatic hypotension and syncope can be increased when Mecamylamine is combined with Duloxetine.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Duloxetine.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Medazepam is combined with Duloxetine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Duloxetine.]
[N06DX01, memantine, Duloxetine may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of serotonin syndrome can be increased when Meperidine is combined with Duloxetine.]
[C01CA11, mephentermine, Duloxetine may increase the tachycardic activities of Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Duloxetine.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Duloxetine.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Duloxetine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Duloxetine.]
[N02AX05, meptazinol, The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Duloxetine.]
[G04BX16, tiopronin, Duloxetine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be decreased when combined with Duloxetine.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Duloxetine.]
[C01CA09, metaraminol, Duloxetine may increase the tachycardic activities of Metaraminol.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Metformin.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Duloxetine.]
[H01CB03, lanreotide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Duloxetine.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be decreased when combined with Duloxetine.]
[A03AB07, methantheline, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Duloxetine.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Duloxetine.]
[J05AF05, lamivudine, Duloxetine may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Duloxetine.]
[S01EC05, methazolamide, The risk or severity of orthostatic hypotension and syncope can be increased when Methazolamide is combined with Duloxetine.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Metergoline is combined with Duloxetine.]
[H03BB02, methimazole, The metabolism of Duloxetine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Duloxetine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Duloxetine.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Duloxetine.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Ziconotide is combined with Duloxetine.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Duloxetine may increase the tachycardic activities of Methoxamine.]
[D05BA02, methoxsalen, Duloxetine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Duloxetine.]
[C03AA08, methyclothiazide, The risk or severity of orthostatic hypotension and syncope can be increased when Methyclothiazide is combined with Duloxetine.]
[C02AB01, methyldopa, The risk or severity of orthostatic hypotension and syncope can be increased when Methyldopa is combined with Duloxetine.]
[V04CG05, methylene blue, Duloxetine may increase the serotonergic activities of Methylene blue.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Duloxetine.]
[G03EK01, methyltestosterone, Duloxetine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Duloxetine.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Duloxetine.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Duloxetine.]
[C03BA08, metolazone, The risk or severity of orthostatic hypotension and syncope can be increased when Metolazone is combined with Duloxetine.]
[C07AB02, metoprolol, The risk or severity of orthostatic hypotension and syncope can be increased when Metoprolol is combined with Duloxetine.]
[P01AB01, metronidazole, The metabolism of Duloxetine can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, Duloxetine may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Duloxetine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Duloxetine.]
[S02AA13, miconazole, The metabolism of Duloxetine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Duloxetine.]
[B01AB07, parnaparin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Duloxetine.]
[C01CA17, midodrine, Duloxetine may increase the tachycardic activities of Midodrine.]
[G03XB01, mifepristone, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Tinzaparin.]
[J05AH01, zanamivir, Duloxetine may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of orthostatic hypotension and syncope can be increased when Valsartan is combined with Duloxetine.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[D11AX01, minoxidil, The risk or severity of orthostatic hypotension and syncope can be increased when Minoxidil is combined with Duloxetine.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Duloxetine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Duloxetine.]
[L03AC01, aldesleukin, The risk or severity of orthostatic hypotension and syncope can be increased when Aldesleukin is combined with Duloxetine.]
[C01BD01, amiodarone, The metabolism of Duloxetine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Duloxetine.]
[N02AA01, morphine, The risk or severity of orthostatic hypotension and syncope can be increased when Morphine is combined with Duloxetine.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Duloxetine.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Duloxetine can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Duloxetine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Duloxetine.]
[L04AA06, mycophenolic acid, Duloxetine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Duloxetine.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Duloxetine.]
[P01BA06, amodiaquine, The metabolism of Duloxetine can be decreased when combined with Amodiaquine.]
[R03BB01, ipratropium bromide, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Duloxetine.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Duloxetine.]
[C07AA12, nadolol, The risk or severity of orthostatic hypotension and syncope can be increased when Nadolol is combined with Duloxetine.]
[J01CA04, amoxicillin, Duloxetine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of orthostatic hypotension and syncope can be increased when Ropinirole is combined with Duloxetine.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Duloxetine.]
[N02AF02, nalbuphine, The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Duloxetine.]
[V03AB15, naloxone, Duloxetine may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Duloxetine.]
[L04AC03, anakinra, The metabolism of Duloxetine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Duloxetine may increase the tachycardic activities of Naphazoline.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Duloxetine.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Naproxen.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Troglitazone.]
[N07XX04, sodium oxybate, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[C01DA05, pentaerythritol tetranitrate, Duloxetine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[N04BX01, tolcapone, The risk or severity of orthostatic hypotension and syncope can be increased when Tolcapone is combined with Duloxetine.]
[S03AA01, neomycin, Duloxetine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of orthostatic hypotension and syncope can be increased when Remifentanil is combined with Duloxetine.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Repaglinide.]
[C01CX08, levosimendan, The risk or severity of orthostatic hypotension and syncope can be increased when Levosimendan is combined with Duloxetine.]
[B01AC17, tirofiban, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Tirofiban.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Duloxetine.]
[J02AA01, amphotericin B, The risk or severity of orthostatic hypotension and syncope can be increased when Amphotericin B is combined with Duloxetine.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[L03AX16, plerixafor, Duloxetine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Duloxetine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Duloxetine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of orthostatic hypotension and syncope can be increased when Telmisartan is combined with Duloxetine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C01CE01, inamrinone, Duloxetine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Duloxetine can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of serotonin syndrome can be increased when Nialamide is combined with Duloxetine.]
[C08CA04, nicardipine, The risk or severity of orthostatic hypotension and syncope can be increased when Nicardipine is combined with Duloxetine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Duloxetine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Duloxetine.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Duloxetine.]
[C08CA05, nifedipine, The risk or severity of orthostatic hypotension and syncope can be increased when Nifedipine is combined with Duloxetine.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of orthostatic hypotension and syncope can be increased when Amyl Nitrite is combined with Duloxetine.]
[C08CA06, nimodipine, The risk or severity of orthostatic hypotension and syncope can be increased when Nimodipine is combined with Duloxetine.]
[C08CA07, nisoldipine, The risk or severity of orthostatic hypotension and syncope can be increased when Nisoldipine is combined with Duloxetine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Duloxetine.]
[C08CA08, nitrendipine, The risk or severity of orthostatic hypotension and syncope can be increased when Nitrendipine is combined with Duloxetine.]
[R07AX01, nitric oxide, The risk or severity of orthostatic hypotension and syncope can be increased when Nitric Oxide is combined with Duloxetine.]
[J01XE01, nitrofurantoin, Duloxetine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Duloxetine.]
[N04BC05, pramipexole, The risk or severity of orthostatic hypotension and syncope can be increased when Pramipexole is combined with Duloxetine.]
[C02DD01, nitroprusside, The risk or severity of orthostatic hypotension and syncope can be increased when Nitroprusside is combined with Duloxetine.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Duloxetine.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Duloxetine.]
[C01CA03, norepinephrine, Duloxetine may increase the tachycardic activities of Norepinephrine.]
[C02KX01, bosentan, The metabolism of Duloxetine can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Duloxetine.]
[R05DA07, noscapine, The metabolism of Duloxetine can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Eptifibatide.]
[G02CA02, nylidrin, Duloxetine may increase the tachycardic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Reviparin.]
[H01CB02, octreotide, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Duloxetine.]
[L04AC04, rilonacept, The metabolism of Duloxetine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Duloxetine can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Opipramol is combined with Duloxetine.]
[N02AA02, opium, The risk or severity of serotonin syndrome can be increased when Opium is combined with Duloxetine.]
[R03CB03, metaproterenol, Duloxetine may increase the tachycardic activities of Orciprenaline.]
[B01AD07, reteplase, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Ancrod.]
[G04CA02, tamsulosin, The risk or severity of orthostatic hypotension and syncope can be increased when Tamsulosin is combined with Duloxetine.]
[J01CF04, oxacillin, Duloxetine may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Duloxetine can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Duloxetine can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Duloxetine.]
[C07AA02, oxprenolol, The risk or severity of orthostatic hypotension and syncope can be increased when Oxprenolol is combined with Duloxetine.]
[N02AA05, oxycodone, The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Duloxetine.]
[C01DX03, oxyfedrine, Duloxetine may increase the tachycardic activities of Oxyfedrine.]
[S01GA04, oxymetazoline, Duloxetine may increase the tachycardic activities of Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Duloxetine.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxypertine is combined with Duloxetine.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Duloxetine.]
[B01AB09, danaparoid, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Duloxetine.]
[J04AB30, capreomycin, Duloxetine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of orthostatic hypotension and syncope can be increased when Papaverine is combined with Duloxetine.]
[N05CC05, paraldehyde, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of serotonin syndrome can be increased when Pargyline is combined with Duloxetine.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Duloxetine.]
[C07AA23, penbutolol, The risk or severity of orthostatic hypotension and syncope can be increased when Penbutolol is combined with Duloxetine.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Penfluridol is combined with Duloxetine.]
[J01CE09, penicillin G procaine, Duloxetine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Duloxetine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Duloxetine.]
[L01XX08, pentostatin, Duloxetine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perazine is combined with Duloxetine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Duloxetine.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Duloxetine.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Duloxetine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Duloxetine.]
[N02AD02, phenazocine, The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Duloxetine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of serotonin syndrome can be increased when Phenelzine is combined with Duloxetine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Duloxetine.]
[B01AA02, phenindione, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Phenindione.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Phenobarbital is combined with Duloxetine.]
[N01AH04, phenoperidine, The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Duloxetine.]
[C04AX02, phenoxybenzamine, The risk or severity of orthostatic hypotension and syncope can be increased when Phenoxybenzamine is combined with Duloxetine.]
[B01AA04, phenprocoumon, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Duloxetine.]
[V03AB36, phentolamine, The risk or severity of orthostatic hypotension and syncope can be increased when Phentolamine is combined with Duloxetine.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Phenylbutazone.]
[S01GA05, phenylephrine, Duloxetine may increase the tachycardic activities of Phenylephrine.]
[R01BA01, phenylpropanolamine, Duloxetine may increase the tachycardic activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Duloxetine.]
[L04AB06, golimumab, The metabolism of Duloxetine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Duloxetine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Duloxetine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[C08CX01, mibefradil, The metabolism of Duloxetine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Duloxetine is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of orthostatic hypotension and syncope can be increased when Pindolol is combined with Duloxetine.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Duloxetine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Duloxetine.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Duloxetine.]
[N06BX03, piracetam, Duloxetine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of orthostatic hypotension and syncope can be increased when Eprosartan is combined with Duloxetine.]
[A02BX03, pirenzepine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Duloxetine.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Duloxetine.]
[J05AG02, delavirdine, The metabolism of Delavirdine can be decreased when combined with Duloxetine.]
[C09CA04, irbesartan, The risk or severity of orthostatic hypotension and syncope can be increased when Irbesartan is combined with Duloxetine.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Proxibarbal is combined with Duloxetine.]
[B01AC13, abciximab, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Alteplase.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Rosiglitazone.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Duloxetine.]
[L04AC08, canakinumab, The metabolism of Duloxetine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of hyponatremia can be increased when Duloxetine is combined with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Ritonavir can be decreased when combined with Duloxetine.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Saxagliptin.]
[B05XA01, potassium chloride, Duloxetine may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Duloxetine.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Duloxetine.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Duloxetine.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Duloxetine.]
[C02CA01, prazosin, The risk or severity of orthostatic hypotension and syncope can be increased when Prazosin is combined with Duloxetine.]
[H02AB07, prednisone, Duloxetine may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Duloxetine.]
[P01BA03, primaquine, The metabolism of Duloxetine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Duloxetine.]
[M04AB01, probenecid, The metabolism of Duloxetine can be decreased when combined with Probenecid.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Duloxetine.]
[S01HA05, procaine, The risk or severity of serotonin syndrome can be increased when Procaine is combined with Duloxetine.]
[L01XB01, procarbazine, The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Duloxetine.]
[C10AB05, fenofibrate, The metabolism of Duloxetine can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Duloxetine.]
[N04AA04, procyclidine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Duloxetine.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Duloxetine.]
[R06AD02, promethazine, The metabolism of Promethazine can be decreased when combined with Duloxetine.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Duloxetine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Propanidid is combined with Duloxetine.]
[A03AB05, propantheline, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Duloxetine.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Duloxetine.]
[N01AX10, propofol, The risk or severity of orthostatic hypotension and syncope can be increased when Propofol is combined with Duloxetine.]
[N02AC04, propoxyphene, The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Duloxetine.]
[C07AA05, propranolol, The risk or severity of orthostatic hypotension and syncope can be increased when Propranolol is combined with Duloxetine.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Duloxetine.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Duloxetine.]
[B01AC09, epoprostenol, The risk or severity of orthostatic hypotension and syncope can be increased when Epoprostenol is combined with Duloxetine.]
[R03DC03, montelukast, The metabolism of Duloxetine can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Duloxetine.]
[R01BA02, pseudoephedrine, Duloxetine may increase the tachycardic activities of Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Duloxetine.]
[N07XX07, dalfampridine, Duloxetine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Duloxetine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Vinbarbital is combined with Duloxetine.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Duloxetine.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Styramate is combined with Duloxetine.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pyrantel is combined with Duloxetine.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Mepyramine is combined with Duloxetine.]
[C01BA01, quinidine, The metabolism of Duloxetine can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Duloxetine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Duloxetine can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of orthostatic hypotension and syncope can be increased when Reserpine is combined with Duloxetine.]
[J05AP01, ribavirin, Duloxetine may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[R03AC05, rimiterol, Duloxetine may increase the tachycardic activities of Rimiterol.]
[G02CA01, ritodrine, Duloxetine may increase the tachycardic activities of Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Duloxetine.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Duloxetine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Duloxetine.]
[N04BD01, selegiline, The risk or severity of serotonin syndrome can be increased when Selegiline is combined with Duloxetine.]
[L01FA03, obinutuzumab, The risk or severity of orthostatic hypotension and syncope can be increased when Obinutuzumab is combined with Duloxetine.]
[J01GB08, sisomicin, Duloxetine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Duloxetine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Duloxetine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of orthostatic hypotension and syncope can be increased when Sotalol is combined with Duloxetine.]
[C03DA01, spironolactone, The risk or severity of orthostatic hypotension and syncope can be increased when Spironolactone is combined with Duloxetine.]
[N06AF04, tranylcypromine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AF01, isocarboxazid, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AF03, phenelzine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N04BD01, selegiline, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
